Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas

다국어 초록 (Multilingual Abstract)

Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.

참고문헌 (Reference)

1 Schuster SJ, "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma" 380 : 45-56, 2019

2 Salles G, "Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma(L-MIND) : a multicentre, prospective, single-arm, phase 2 study" 21 : 978-988, 2020

3 Gisselbrecht C, "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era" 28 : 4184-4190, 2010

4 Coiffier B, "Rituximab therapy in malignant lymphoma" 26 : 3603-3613, 2007

5 Budde LE, "Results of an ongoing phase 2 study of brentuximab vedotin with rchp as frontline therapy in patients with high-intermediate/high-risk diffuse large B cell lymphoma(DLBCL)" 128 (128): 104-104, 2016

6 Zinzani PL, "Re-mind study: comparison of tafasitamab+lenalidomide (L-MIND) vs lenalidomide monotherapy (REAL-world data) in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma" S238-, 2020

7 Younes A, "Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma" 37 : 1285-1295, 2019

8 Sehn LH, "Randomized phase 2 trial of polatuzumab vedotin(POLA)with bendamustine and rituximab(BR)in relapsed/refractory(R/R)FL and DLBCL" (36) : 7507-7507, 2018

9 Pileri SA, "Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1in the absence of immunoglobulins" 162 : 243-253, 2003

10 Horton HM, "Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia" 68 : 8049-8057, 2008

11 Bonavida B, "Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens : strategies to overcome resistance" 41 : 667-677, 2014

12 Morschhauser F, "Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma : final results from a phase 2 randomised study(ROMULUS)" 6 : e254-65, 2019

13 Sehn LH, "Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma" 38 : 155-165, 2020

14 Landsburg DJ, "Outcomes of patients with double-hit lymphoma who achieve first complete remission" 35 : 2260-2267, 2017

15 Crump M, "Outcomes in refractory diffuse large B-cell lymphoma : results from the international SCHOLAR-1 study" 130 : 1800-1808, 2017

16 Vitolo U, "Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma" 35 : 3529-3537, 2017

17 Marcus R, "Obinutuzumab for the first-line treatment of follicular lymphoma" 377 : 1331-1344, 2017

18 Kreitman RJ, "Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia" 32 : 1768-1777, 2018

19 Shaffer AL, "Lymphoid malignancies : the dark side of B-cell differentiation" 2 : 920-932, 2002

20 Dufner V, "Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab" 3 : 2491-2498, 2019

21 Abramson JS, "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001) : a multicentre seamless design study" 396 : 839-852, 2020

22 Carter RH, "Germinal center structure and function : lessons from CD19" 20 : 43-48, 2008

23 Casulo C, "Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : an analysis from the National LymphoCare Study" 33 : 2516-2522, 2015

24 Bartlett NL, "Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma : clinical outcomes of the phase III intergroup trial alliance/CALGB 50303" 37 : 1790-1799, 2019

25 Davis RE, "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma" 463 : 88-92, 2010

26 Hu S, "CD30expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature : a report from the International DLBCL Rituximab-CHOP Consortium Program Study" 121 : 2715-2724, 2013

27 Higgins JP, "CD30 expression is common in mediastinal large B-cell lymphoma" 112 : 241-247, 1999

28 Slack GW, "CD30 expression in de novo diffuse large B-cell lymphoma : a population-based study from British Columbia" 167 : 608-617, 2014

29 Jacobsen ED, "Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression" 125 : 1394-1402, 2015

30 Goebeler ME, "Bispecific T-cell engager(BiTE)antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma : final results from a phase I study" 34 : 1104-1111, 2016

31 Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma" 377 : 2531-2544, 2017

32 Kosmas C, "Anti-CD20-based therapy of B cell lymphoma : state of the art" 16 : 2004-2015, 2002

33 Jurczak W, "A phase IIa, open-label, multicenter study of single-agent tafasitamab(MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma : long-term follow-up, final analysis" (134) : 4078-4078, 2019